Non-tuberculous mycobacteria (NTM) in Zambia: prevalence, clinical, radiological and microbiological characteristics by unknown
RESEARCH ARTICLE Open Access
Non-tuberculous mycobacteria (NTM) in
Zambia: prevalence, clinical, radiological
and microbiological characteristics
Pascalina Chanda-Kapata1,2*, Nathan Kapata2,3, Eveline Klinkenberg4,5, Lutinala Mulenga6, Mathias Tembo7,
Patrick Katemangwe8, Veronica Sunkutu9, Peter Mwaba1 and Martin P. Grobusch2
Abstract
Background: Non-tuberculous mycobacteria (NTM) infection is an emerging health problem. We present here the
Zambia-specific national level data of prevalence, symptomatic, radiological and microbiological characteristics of
NTM, using results from a national Tuberculosis (TB) prevalence survey.
Methods: This was a cross-sectional study of the prevalence of NTM among adults aged 15 years and above, who
were participants in a national TB prevalence survey. Participants who had either an abnormal chest x-ray or were
symptomatic were considered presumptive TB cases and submitted sputum for smear and culture analysis. HIV testing
was performed on an opt-out basis. Symptomatic NTM prevalence was estimated from individual level analysis.
Results: Of the 6,123 individuals with presumptive TB, 923 (15.1 %) were found to have NTM, 13 (0.2 %) were MTB/
NTM co-infected and 338 (5.5 %) were contaminated (indeterminate). The prevalence of symptomatic NTM was found
to be 1,477/100,000 [95 % CI 1010–1943]. Smear positivity, history of cough or chest pain and HIV positivity were risk
factors for NTM.
Conclusion: This first study to estimate the national prevalence of NTM in Zambia indicates that the burden is high.
The NTM occurrence in Zambia constitutes both a public health and ethical issue requiring action from health
managers.
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Background
Non-tuberculosis Mycobacteria (NTM) refer to all
Mycobacterium species other than the pathogens of the
M.tuberculosis complex (MTBC), M. leprae and M.
ulcerans, and rarely cause disease in humans. However,
they may cause disease in individuals with pre-existing
lung disease or immunodeficiency while some species
may cause disease in elderly women without underlying
pulmonary disease or immunodeficiency [1, 2] NTM are
commonly found in the environment and can be isolated
from sources such as soil, milk, dust, animals and birds
[1]. Over 140 species of NTM have been reported in
literature with the majority of these species rarely being
isolated in clinical samples [3]. The most common group
of NTM is the Mycobacterium avium complex (MAC)
comprising the clinically important members M.
intracellulare M. avium and M.chimaera. Other poten-
tially pathogenic NTM species include M. chelonae, M.
kansasii, M. xenopi, M. marinum, M. abscessus and M.
fortuitum [4–6].
Among the diseases caused by NTM, pulmonary
disease is the most frequent, followed by lymphadenitis
in children, skin disease caused by Mycobacterium mari-
num (especially common in fish tank owners) and other
extra-pulmonary or disseminated infections [3, 5, 7].
NTM can exhibit clinical and radiographic features that
are similar to those by MTBC [8, 9] especially in persons
with progressed cellular immune dysfunction. Although
this is not the case in all studies, in Brazil, Dos Santos
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and colleagues [10] compared radiological features
between MTBC and NTM and found some differences
in patients with AIDS. Species differentiation is needed
to tell NTMs safely apart from MTBC in individuals
suggestive of having TB [11]. However, distinguishing
between MTBC and NTM diseases may be a challenge,
especially in low resource settings where microscopy is
the mainstay for MTBC diagnosis. Although microscopy
for acid-fast bacilli (AFB) allows for rapid diagnosis of
mycobacteria, it does not, however, differentiate M.
tuberculosis from NTM. A recent study in Nigeria [12]
showed that failure to characterize AFB positive NTM
lung infections has led to misclassification and incorrect
treatment as pulmonary tuberculosis since all diagnosed
sputum smear positive patients are placed on TB
treatment. In order to differentiate the two, traditional
culture methods may be required but these may take up
to 6 weeks [13].
There is limited literature available on the extent of
the burden of pulmonary disease due to NTM in sub-
Saharan Africa. Studies conducted in the later part of
the 1950s and early 1960s [14] identifying mycobacterial
groups using traditional tools like characteristics such as
growth rate and morphology reported the isolation of
NTM from both tuberculosis patients and the general
public in some African countries, Zambia included. The
study as a whole found that the frequency of NTM
strains differed; 19.8 % NTM cases were identified
among 657 cultures isolated from specimens of a general
population survey, whereas only 1.1 % NTM cases were
identified from 7,580 cultures from tuberculosis patients.
Studies conducted in Nigeria and Tanzania suggest
NTM infections could be associated with HIV co-
infection [15–17]. A prospective cohort study among
HIV positive patients in Cote d’Ivoire reported a 10
times higher incidence of NTM infection among
patients with baseline CD4 cell counts below 100 cells/
mm3 [18].
In Zambia, clinically relevant infection due to NTM
was shown to occur in both HIV-positive and HIV-
negative patients in a rural hospital [19]. In another
study, Buijtels and colleagues [20] evaluated the clinical
relevance of NTM isolated from chronically ill patients
and healthy controls in Zambia and found that the pro-
portion of NTM-positive sputum samples was signifi-
cantly higher in the patient group (11 %) than in
controls (6 %). The most frequently isolated NTM was
M. avium complex. Unlike HIV, sex and age; being
underweight and consumption of tap water were identi-
fied as risk factors for NTM infection.
While it is acknowledged that the prevalence and the
species of NTM isolated is increasing [5, 7, 8], the
clinical relevance and characteristics of the NTMs in dif-
ferent settings remain to be established.
We present here the Zambia-specific data on national
level prevalence, symptomatic, radiological and micro-
biological characteristics of NTMs, using results from a
national Tuberculosis prevalence survey. To our know-
ledge, this is the first large data set to explore the preva-
lence of NTM from a national representative sample
covering all provinces and to discuss radiological charac-
teristics of NTM in Zambia.
Methods
This was a cross-sectional study of the prevalence of
NTM among adults aged 15 years and above, who were
participants in a national TB prevalence survey. All
individuals with an abnormal chest x-ray or positive
symptom screening result (i.e. cough or chest pain, or
fever lasting more than 2 weeks or more) were requested
to submit two sputum samples; one on the spot and
another in the morning. The samples were then trans-
ported in cooler boxes packed with cold gel within 24 h
of collection to each of the three central reference
laboratories (CRLs) for processing. At the laboratories,
the sputum samples were first decontaminated in 1 %
sodium dydroxide (NaOH) working solution for 15 min
and then stained for AFB using the Auramine-Phenol
method. The smears were graded as smear positive for
mycobacterial infection using both qualitative and quan-
titative grading methods. Thereafter, the samples were
cultured using liquid media by mycobacteria growth
indicator tube (MGIT) (BD BACTECTM). Mycobacterial
growth was detected and identified as either MTB or
NTM using the capilia (TAUNS) method. The labora-
tory team was blinded to the radiology or symptom
status of the study participants; they only had a Personal
Identification Number (PIN) and sample.
Before collection of sputum samples; each symptom-
atic survey participant also underwent an in-depth ques-
tionnaire. Initial reading of chest radiographs was done
by medical officers in the field and classified as either
normal or abnormal. All images subsequently underwent
reading by expert radiologists who classified the images
using a pre-defined criteria [21] as follows:
 N=Normal
 AD - NS = Abnormality detected - not significant
 ADS-NA = Abnormality detected, significant no
active disease
 ADS-NTB =Abnormality detected, significant not-TB
 ADS-TB = Abnormality detected, significant TB
All the abnormal ‘not TB’ images were then re-read to
further specify the abnormality so as to make a radio-
logical diagnosis. The central reading by radiologists was
performed independent of the microbiology results.
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The HIV status for each of the NTM cases was estab-
lished using the HIV testing results which were obtained
using a separate consent during field level HIV screening
of survey participants. The screening test used was
Determine® HIV-1/2 (Inverness Medical Japan, Co, Ltd)
and all positives were further confirmed by Unigold®
HIV-1/2 (Trinity Biotech, Wicklow, Ireland). Discordant
results (positive on Determine® but negative on
Unigold®) were recorded as indeterminate.
At the central data management unit, the results of
the symptom screening, chest x-ray screening and
laboratory results were merged to create one final data-
base for analysis. The files were merged using PINs
which were unique to each participant in the survey.
This was done to ensure that for each NTM, data on
radiology, clinical history and microbiology was
complete. Only the data manager had access to the
complete merged data set. This was done to ensure con-
fidentiality but also to reduce bias during case detection
or diagnosis.
Data analysis was performed using STATA version 12.
Means and frequencies were generated taking into ac-
count of the Random Standard Errors using the default
“svy” command during analysis.
Chi-square tests were performed to establish relation-
ship between the categorical or binary variables. Linear
regression analysis was done to show the association
between NTM and different exposure variables such as
HIV status, smear positivity, history of cough or chest
pain or fever.
The prevalence of NTM was estimated using cluster
level and individual level analysis as recommended by
Floyd et al. [22].
The study protocol was cleared by the University of
Zambia Biomedical Research Ethics Committee
(UNZABREC) No: 020-08-12. Authorisation to conduct
the survey was sought in line with the existing national
policies and guidelines at national, provincial and district
levels. Written informed consent was obtained from all
individuals who agreed to participate in the survey.
Results
Of the 6,123 with presumptive MTB, 923 (15.1 %) were
found to have NTM, 265 (4.3 %) were MTB, 13 (0.2 %)
were MTB/NTM co-infected and 338 (5.5 %) were
contaminated (indeterminate). Basic cohort characteristics
are shown in Table 1. Most of the participants with NTM
were from the lowest-wealth quintile. 71 % of the NTM
infected participants were symptomatic, either having a
cough and/or chest pain and/or fever for two weeks or
more. 52 % of NTM infected participants had an abnor-
mal field chest x-ray reading. 23 % (210) of the partici-
pants with NTM were both symptomatic and had an
abnormal CXR reading at field level. Chest x-ray results
were not available for 2/923 participants with NTM.
Some of the abnormal chest radiographs showed
evidence of bronchiectasis, nodules, fibrosis or cavitation
as shown in Table 2. Majority of the participants with
NTM had negative smear (94.5 %) and 62 % were
HIV negative.
Comparing the three cardinal symptoms collected in
the survey (Table 3); 277 individuals with NTM had no
history of either cough or chest pain or fever and 52
reported a history of fever only without any of the other
two (chest pain and cough). A total of 423 individuals
reported having all the three symptoms.
Table 1 Background characteristics of the survey participants
with NTM
Variable Number Percent (%)
Sex (N = 923)
Male 446 48.32
Female 477 51.68
Setting (N = 923)
Rural residence 708 76.71
Urban residence 215 23.29







Education (N = 923)




Wealth Quintile (N = 834)
Lowest 215 25.78




Symptom Screening (N = 923)
Postive 655 70.96
Negative 268 29.04
Field chest x-ray (N = 923)
Normal 443 48.00
Abnormal 478 51.79
Not done 2 0.22
Chanda-Kapata et al. BMC Infectious Diseases  (2015) 15:500 Page 3 of 7
The risk factors of NTM included smear positivity;
history of cough or chest pain or fever or weight loss
and being HIV positive as shown in Table 4.
Prevalence of symptomatic NTM among TB survey
participants aged 15 years and above was found to be
1,477/100,000 [95 % CI 1010–1943]. Symptomatic NTM
prevalence was found to be significantly higher among
the rural than urban participants (1927 vs 642/100,000
population). However, there was no significant difference
in the prevalence of symptomatic NTM by sex (1,577/
100,000 versus 1403/100,000). Among the provinces,
NTM prevalence was highest in Western (9,824/100,000)
and lowest in Copperbelt (309/100,000) (Table 5). The
participation rate for Western province was low hence this
may have resulted into the wide confidence interval of the
prevalence estimate.
The prevalence of symptomatic NTM increased with
participant’s age from 452/100,000 among those aged
15–24 years to 5160/100,000 among those aged 65 years
and above. The symptomatic NTM prevalence was
highest among the lower wealth quintiles and participants
without schooling. Participants with bacteriologically con-
firmed MTB had significantly higher symptomatic NTM
prevalence than those without (6773 vs 1468/100,000). Par-
ticipants with smear positive TB had a higher prevalence of
symptomatic NTM than those with a negative smear (8527
vs 1479/100,000). Considering HIV status, the HIV positive
participants had higher symptomatic NTM prevalence than
the HIV negative counterparts (2187 vs 1549/100,000) but
the difference was not significant.
Discussion
This study represents a first attempt to quantify NTM
prevalence nation-wide in Zambia. The focus was on
individuals with NTM coupled with both symptom and
radiological profiles. The high prevalence of NTM
among symptomatic participants found in this popula-
tion based study demonstrates that NTM is a public
health problem. There is a need to further identify the
species and come up with case management guidelines
in order to appropriately manage the people in whom
NTM is causing illness. Symptomatic NTM prevalence
was found to be approximately two times higher than
MTB and 14 % of the smear positives were found to be
NTM [23]. Therefore, NTM patients could potentially
be mismanaged as MTB. Besides a public health issue
this is also an ethical issue requiring no further neglect.
Although the World Health Organization (WHO) has
described Neglected Tropical Diseases (NTDs), this list
conspicuously does not yet include any of the NTM.
As smears are routinely used to diagnose TB and to
initiate treatment, it could be that symptomatic NTM
cases seeking care in health facilities are misdiagnosed
and placed on TB treatment. Without adequate clinical
response, these cases may subsequently be misdiagnosed
as TB treatment failures. Thus, false MTB-positives may
in fact be clinical NTM and if the treatment outcomes
do not improve; the patient may mistakenly be classified
as MDR-TB. Such patient mismanagement may
negatively impact the health status of the individual and
consequently pose additional cost to the health system.
Therefore, appropriate NTM case management is
required in order to effectively and efficiently manage
the MTB problem.
Table 2 Clinical, radiological and microbiological characteristics
of individuals with NTM
Clinical Symptoms: Number Percent (%)
Cough 489 52.98
Fever 324 35.10
Chest pain 656 71.07






Miliary TB 19 2.06







Not available 297 32.18
Table 3 Comparison of the occurrence of symptoms among
individuals with NTM (Absolute numbers)
NTM individual with fever and NTM individual with chest pain
Cough No Yes
No Yes No Yes
No 277 394 52 181
Yes 138 353 41 423
Table 4 Risk factors of Non-tuberculous mycobacteria
Variable Number (%) Odds ratio [95 % CI] p-value
Smear positive 51 (5.53) 2.01 [1.82–2.21] 0.000
Cough 489 (52.98) 0.804 [0.723–0.895] 0.000
Chest pain 656 (71.07) 1.25 [1.11–1.40] 0.000
Fever at night 324 (35.10) 1.13 [1.01–1.27] 0.027
Unintentional weight loss 329 (35.64) 0.855 [0.763–0.953] 0.007
HIV positive 54 (5.85) 0.941 [0.913–0.970] 0.000
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Table 5 Symptomatic Non-tuberculous mycobacteria prevalence per 100,000 adult population















Age group (years) and sex Male Female
15–34 712 (447–976) 661 (392–930)
35–54 1911 (1363–2460) 1778 (954–2601)
55+ 4124 (2822–5426) 3841 (1975–5707)
Wealth quintile
Lowest 2582 1628–3535





No schooling 3495 2010–4980
Primary school 1858 1301–2415
Secondary school 752 512–992








HIV negative 1549 1008–2090
HIV positive 2187 1428–2946
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The radiological abnormalities for NTM observed in
this survey are consistent with what has been reported
elsewhere [5]. The pulmonary presentation of NTM was
characterized by the presence of bronchiectasis; cavita-
tion; pneumoconiosis, fibrosis and nodules. The cardinal
symptoms of fever, chest pain and unintentional weight
loss were prevalent in the survey participants with
NTM. This may suggest that NTM in Zambia is causing
symptomatic disease.
The higher NTM prevalence among HIV positive indi-
viduals brings a further challenge of managing NTM/
HIV and its associated side effects for potential patients.
Even though, the burden of NTM was higher among the
HIV positive, there is also a substantial burden among
the HIV negative that cannot be ignored.
The NTM prevalence in Zambia seems to increase
with age. This was true for both male and female
supporting earlier evidence from Greece and the United
States of America [5, 24, 25]. Nonetheless, it will be
important to establish if the species causing disease are
occurring in similar proportions among the male and
females since reported symptoms were found to differ
by gender.
Studies from Nigeria, Tanzania and South Africa have
shown that NTMs may be occurring among patients
seeking care for MTB [15, 16, 26] with varying frequency
by geographical locations [27]. The NTM prevalence
isolated in this Zambia survey is higher than what was
found in Oregon in the United States of America and
Ontario in Canada [28, 29]. However, the differences in
the study population and analytical approach partially
contribute to the variations. Our study also suggests
potential interaction or misdiagnosis with MTB as in the
American and Canada studies. Therefore, a comprehen-
sive multi-country evaluation of NTM is needed to bet-
ter understand the extent of the NTM burden on the
globe and design strategic action.
Given the dimension of the problem and the conse-
quences for the individual patient as well as the health
system in terms of potential to cause negative impact on
treatment cost and duration, and possible spread of the
organism, speciation and resistance testing may be cost-
effective in the long term in order to enable correct and
timely treatment of patients.
A potential limitation is that the study was conducted
within the national TB prevalence survey design, as a
result, we are unable to fully apply the existing NTM
disease classification criteria because the methods used
for sputum collection were with the primary purpose of
estimating MTB prevalence. However, the availability of
samples from various subnational levels provides oppor-
tunity for better estimation of the NTM burden and
provides geographic guidance for potential program-
matic focus.
This study is the first attempt to estimate the national
burden of NTM in Zambia. Further studies are rec-
ommended to fully understand causal and etiological
pathways.
Conclusions
Our data confirm that the problem of NTM is substantial
in Zambia. Synopsis of epidemiological, clinical and
radiological information is needed to support an informed
decision on whether a patient has disease resulting from
MTBC or NTM infection. Rigorous surveillance strategies
are required to curb the further spread of this neglected
mycobacterial disease.
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